STI Stock Trade Intelligence
ATH

ALTERITY THERAPEUTICS LIMITED

Health Care · ASX:ATH
$0.2250
▼ -10.00%
Market cap
$52M
Turnover
$72,726
Last price
$0.2250
Day change
-10.00%
Announcements
13
Range, past year
Open 0.009 · Low 0.007 · Now 0.225 · High 0.785
Open ATH in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

ATH momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
32/100
Wyckoff phase
Accumulation13d
Trend stage
Neutral
1 Day
-10.0%
1 Week
-25.0%
1 Month
-27.4%
RSI
35
Avg daily range
12.7%

ALTERITY THERAPEUTICS LIMITED scores 32 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 13 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.94 — highly linear uptrend
Points to watch
  • 60d drawdown -56.7%
  • High volatility (ATR 12.7%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
ATH appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

ATH announcements

Recent price-sensitive releases.
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-08-31 $4.2M Options Underwriting Agreement Executed Issued Capital - Other
  • 2026-08-28 Appendix 4E and 2026 Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-12 Granted New U.S. Composition of Matter Patent for ATH434 Progress Report
  • 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-09 ATH Receives A$3.98m R&D Tax Incentive
  • 2026-07-07 FDA Meeting Minutes Confirm Registrational Path for ATH434
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.